Cytochrome p450 pharmacogenetics in african populations: Implications for public health

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 6, 2014, Pages 769-785

  Dandara, Collet ^a   Swart, Marelize ^a   Mpeta, Bafokeng ^a   Wonkam, Ambroise ^a   Masimirembwa, Collen ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b African Institute of Biomedical Science and Technology   (Zimbabwe)

Author keywords

Africa; Cytochrome P450; Genetic diversity; Genetics variation; Pharmacogenetics; Pharmacogenomics; Public health

Indexed keywords

ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EFAVIRENZ; NEUROLEPTIC AGENT; TUBERCULOSTATIC AGENT; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ASIA; DRUG METABOLISM; ETHNIC DIFFERENCE; EUROPE; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHARMACOGENETICS; PUBLIC HEALTH; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; REVIEW; THROMBOEMBOLISM; ASIAN CONTINENTAL ANCESTRY GROUP; BIOTRANSFORMATION; BLACK PERSON; CAUCASIAN; GENETICS;

AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HUMANS; POLYMORPHISM, GENETIC; PUBLIC HEALTH;

EID: 84901054563     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.894020     Document Type: Review

References (122)

1. Giacomini KM, Yee SW, Ratain MJ, et al. Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med 2012;4:153-18
2. Sirugo G, Hennig BJ, Adeyemo AA, et al. Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics. Hum Genet 2008;123:557-98
3. Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet 2008;9:403-33
4. WHO World Health Statistics -GHIPI, WHO Report
5. Corbett EL, Marston B, Churchyard GJ, et al. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006;367:926-37
6. Sachs J, Malaney P. The economic and social burden of malaria. Nature 2002;415:680-5
7. Mhalu FS. Burden of diseases in poor resource countries: meeting the challenges of combating HIV/AIDS, tuberculosis and malaria. Tanzan Health Res Bull 2005;7:179-84
8. Ross CJ, Visscher H, Rassekh SR, et al. Pharmacogenomics of serious adverse drug reactions in pediatric oncology. J Popul Ther Clin Pharmacol 2011;18:134-51
9. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5
10. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000;109:87-94
11. Haga SB, Ginsburg GS. Prescribing BiDil: is it black and white? J Am Coll Cardiol 2006;48:12-14
12. Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7
13. Zoratti R. A review on ethnic differences in plasma triglycerides and high-density-lipoprotein cholesterol: is the lipid pattern the key factor for the low coronary heart disease rate in people of African origin? Eur J Epidemiol 1998;14:9-21
14. Gaines K, Burke G. Ethnic differences in stroke: black-white differences in the United States population. SECORDS Investigators. Southeastern Consortium on Racial Differences in Stroke. Neuroepidemiology 1995;14:209-39
15. Sun HY, Hung CC, Lin PH, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother 2007;60:599-604
16. Campbell MC, Tishkoff SA. The evolution of human genetic and phenotypic variation in Africa. Curr Biol 2010;20:166-73
17. Scheinfeldt LB, Soi S, Tishkoff SA. Colloquium paper: working toward a synthesis of archaeological, linguistic, and genetic data for inferring African population history. Proc Natl Acad Sci USA 2010;107(Suppl 2):8931-8
18. Bryc K, Auton A, Nelson MR, et al. Genome-wide patterns of population structure and admixture in West Africans and African Americans. Proc Natl Acad Sci USA 2010;107:786-91
19. Tishkoff SA, Gonder MK, Henn BM, et al. History of click-speaking populations of Africa inferred from mtDNA and Y chromosome genetic variation. Mol Biol Evol 2007;24:2180-95
20. Kudzi W, Adjei GO, Ofori-Adjei D, et al. Pharmacogenetics in ghana: reviewing the evidence. Ghana Med J 2011;45:73-80
21. Kudzi W, Dodoo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 2009;10:124
22. Kudzi W, Dodoo AN, Mills JJ. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet 2010;11:111
23. Ngaimisi E, Habtewold A, Minzi O, et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One 2013;8:67946
24. Swart M, Ren Y, Smith P, et al. ABCB1 4036A>G and 1236C>T polymorphisms affect plasma efavirenz levels in South African HIV/AIDS patients. Front Genet 2012;3:236
25. Swart M, Skelton M, Wonkam A, et al. CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 Polymorphisms in Two Bantu-Speaking Populations from Cameroon and South Africa: implications for Global Pharmacogenetics. Curr Pharmacogenomics Person Med 2012;10:43-53
26. Swart M, Whitehorn H, Ren Y, et al. PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/ AIDS patients. BMC Med Genet 2012;13:112
27. Habtewold A, Amogne W, Makonnen E, et al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother 2011;66:2350-61
28. Yimer G, Amogne W, Habtewold A, et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenzbased HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J 2012;12:499-506
29. Kampira E, Kumwenda J, van Oosterhout JJ, et al. Mitochondrial DNA subhaplogroups L0a2 and L2a modify susceptibility to peripheral neuropathy in malawian adults on stavudine containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2013;63:647-52
30. Mukonzo JK, Okwera A, Nakasujja N, et al. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis 2013;13:261
31. Hansen NT, Brunak S, Altman RB. Generating genome-scale candidate gene lists for pharmacogenomics. Clin Pharmacol Ther 2009;86:183-9
32. Kitzmiller JP, Groen DK, Phelps MA, et al. Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med 2011;78:243-57
33. The Pharmacogenomics Knowledge Base (PharmGKB). Available from: www. pharmgkb.org
34. Hernandez-Boussard T, Woon M, Klein TE, et al. Integrating large-scale genotype and phenotype data. Omics 2006;10:545-54
35. Aklillu E, Dandara C, Bertilsson L, et al. Pharmacogenetics of Cytochrome P450s in African Populations: Clinical and Molecular Evolutionary Implications. Chapter Category: Pharmacogenomics. From the book Pharmacogenomics in Admixed Populations. LANDES Bioscience, Austin, TX; 2007
36. Masimirembwa CM, Hasler JA. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants. Brain Res Bull 1997;44:561-71
37. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008;21:70-83
38. Bains RK, Kovacevic M, Plaster CA, et al. Molecular diversity and population structure at the Cytochrome P450 3A5 gene in Africa. BMC Genet 2013;14:34
39. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007;76:391-6
40. Rendic S, Guengerich FP. Update information on drug metabolism systems - 2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters. Curr Drug Metab 2010;11:4-84
41. Tishkoff SA, Williams SM. Genetic analysis of African populations: human evolution and complex disease. Nat Rev Genet 2002;3:611-21
42. Lonjou C, Zhang W, Collins A, et al. Linkage disequilibrium in human populations. Proc Natl Acad Sci USA 2003;100:6069-74
43. Masimirembwa CM, Johansson I, Hasler JA, et al. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993;3:275-80
44. Masimirembwa C, Bertilsson L, Johansson I, et al. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995;57:656-61
45. Masimirembwa C, Persson I, Bertilsson L, et al. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996;42:713-19
46. Masimirembwa C, Hasler J, Bertilssons L, et al. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 1996;51:117-22
47. Dandara C, Masimirembwa CM, Magimba A, et al. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol 2001;57:11-17
48. Bapiro TE, Hasler JA, Ridderstrom M, et al. The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem Pharmacol 2002;64:1387-98
49. Drogemoller BI, Niehaus DJ, Chiliza B, et al. Patterns of variation influencing antipsychotic treatment outcomes in South African first-episode schizophrenia patients. Pharmacogenomics 2014;15:189-99
50. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte - an update of guidelines. Clin Pharmacol Ther 2011;89:662-73
51. Alessandrini M, Asfaha S, Dodgen TM, et al. Cytochrome P450 pharmacogenetics in African populations. Drug Metab Rev 2013;45:253-75
52. Matimba A, Oluka MN, Ebeshi BU, et al. Establishment of a biobank and pharmacogenetics database of African populations. Eur J Hum Genet 2008;16:780-3
53. Griese EU, Asante-Poku S, Ofori-Adjei D, et al. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 1999;9:715-23
54. Bathum L, Skjelbo E, Mutabingwa TK, et al. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. Br J Clin Pharmacol 1999;48:395-401
55. Herrlin K, Massele AY, Jande M, et al. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 1998;64:391-401
56. Aklillu E, Herrlin K, Gustafsson LL, et al. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 2002;12:375-83
57. Simooya OO, Njunju E, Hodjegan AR, et al. Debrisoquine and metoprolol oxidation in Zambians: a population study. Pharmacogenetics 1993;3:205-8
58. Simooya OO, Sijumbil G, Lennard MS, et al. Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol 1998;45:315-17
59. Gaedigk A, Coetsee C. The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol 2008;64:465-75
60. Wright GE, Niehaus DJ, Drogemoller BI, et al. Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 2010;74:340-50
61. Dodgen TM, Hochfeld WE, Fickl H, et al. Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study. BMC Med Genet 2013;14:20
62. Wennerholm A, Dandara C, Sayi J, et al. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 2002;71:77-88
63. Lum DW, Perel P, Hingorani AD, et al. CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLoS One 2013;8:76648
64. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001;104:173-92
65. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations - ready for clinical practice? Nat Rev Drug Discov 2005;4:639-47
66. Thompson EE, Kuttab-Boulos H, Witonsky D, et al. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004;75:1059-69
67. Byakika-Kibwika P, Lamorde M, Mayito J, et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012;67:2213-21
68. Nemaura T, Dhoro M, Nhachi C, et al. Evaluation of the prevalence, progression and severity of common adverse reactions (Lipodystrophy, CNS, peripheral neuropathy, and hypersensitivity reactions) associated with Anti-Retroviral Therapy (ART)and anti-tuberculosis treatment in outpatients in Zimbabwe. J AIDS Clin Res 2013;4:1-7
69. di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 2009;19:300-9
70. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003;306:287-300
71. Holzinger ER, Grady B, Ritchie MD, et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics 2012;22:858-67
72. Bienvenu E, Swart M, Dandara C, et al. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients. Antiviral Res 2014;102:44-53
73. Gounden V, van Niekerk C, Snyman T, et al. Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 2010;7:32
74. Swart M, Skelton M, Ren Y, et al. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet Genomics 2013;23:415-27
75. Sarfo FS, Zhang Y, Egan D, et al. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother 2014;69:491-9
76. Mutwa PR, Fillekes Q, Malgaz M, et al. Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms. J Acquir Immune Defic Syndr 2012;60:400-4
77. Strehlau R, Martens L, Coovadia A, et al. Absence seizures associated with efavirenz initiation. Pediatr Infect Dis J 2011;30:1001-3
78. Sanchez A, Cabrera S, Santos D, et al. Population pharmacokinetic/ pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. Antimicrob Agents Chemother 2011;55:5314-24
79. Cabrera SE, Santos D, Valverde MP, et al. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother 2009;53:2791-8
80. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. Aids 2001;15:71-5
81. Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009;5:1000433
82. Zhao F, Loke C, Rankin SC, et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 2004;76:210-19
83. DeLozier TC, Lee SC, Coulter SJ, et al. Functional characterization of novel allelic variants of CYP2C9 recently discovered in Southeast Asians. J Pharmacol Exp Ther 2005;315:1085-90
84. Limdi NA, Arnett DK, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 2008;9:511-26
85. Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy 2008;28:1084-97
86. Scott SA, Khasawneh R, Peter I, et al. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010;11:781-91
87. Pathare AV, Al Zadjali S, Misquith R, et al. Warfarin pharmacogenetics: polymorphisms of the CYP2C9, CYP4F2, and VKORC1 loci in a genetically admixed Omani population. Hum Biol 2012;84:67-77
88. Alwan A, Modell B. Recommendations for introducing genetics services in developing countries. Nat Rev Genet 2003;4:61-8
89. Hardy BJ, Seguin B, Goodsaid F, et al. The next steps for genomic medicine: challenges and opportunities for the developing world. Nat Rev Genet 2008;9(Suppl 1):S23-7
90. Nordling L. African nations vow to support science. Nature 2010;465:994-5
91. Human Heredity and Health in Africa (H3Africa) initiative to the Wellcome Trust and the National Institutes of Health. Harnessing genomic technologies toward improving health in Africa: opportunities and challenges. Available from: http://h3africa.org/images/PDF/ h3africawhitepaper.pdf
92. Wonkam A, Njamnshi AK, Angwafo FF III. Knowledge and attitudes concerning medical genetics amongst physicians and medical students in Cameroon (sub-Saharan Africa). Genet Med 2006;8:331-8
93. Peprah E, Wonkam A. Biomedical research, a tool to address the health issues that affect African populations. Global Health 2013;9:50
94. African Society of Human Genetics (AfSHG). Available from: www.afshg.org
95. Dandara C, Adebamowo C, de Vries J, et al. An idea whose time has come? An African foresight observatory on genomics medicine and data-intensive global science. Curr Pharmacogenomics Person Med 2012;10:7-15
96. Ozdemir V, Kolker E, Hotez PJ, et al. Ready to put metadata on the post-2015 development agenda? Linking data publications to responsible innovation and science diplomacy. Omics 2014;18:1-9
97. Kolker E, Ozdemir V, Martens L, et al. Toward more transparent and reproducible omics studies through a common metadata checklist and data publications. Omics 2014;18:10-14
98. U.S. Food and Drug Administration. Available from: www.fda.gov/drugs
99. Lee EJ, Jeyaseelan K. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br J Clin Pharmacol 1994;37:605-7
100. Zuo LJ, Guo T, Xia DY, et al. Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations. Genet Test Mol Biomarkers 2012;16:102-8
101. Sistonen J, Sajantila A, Lao O, et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007;17:93-101
102. Xie HG, Prasad HC, Kim RB, et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002;54:1257-70
103. Saeki M, Saito Y, Nakamura T, et al. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum Mutat 2003;21:653
104. Kubota T, Yamaura Y, Ohkawa N, et al. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 2000;50:31-4
105. Bae JW, Kim HK, Kim JH, et al. Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 2005;60:418-22
106. Lee SJ, Lee SS, Jung HJ, et al. Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans. Drug Metab Dispos 2009;37:1464-70
107. Menoyo A, del Rio E, Baiget M. Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. Cell Biochem Funct 2006;24:381-5
108. Crescenti A, Mas S, Gasso P, et al. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis. Clin Exp Pharmacol Physiol 2007;34:992-7
109. van Schaik RH, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002;48:1668-71
110. Roy JN, Lajoie J, Zijenah LS, et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 2005;33:884-7
111. Ikediobi O, Aouizerat B, Xiao Y, et al. Analysis of pharmacogenetic traits in two distinct South African populations. Hum Genomics 2011;5:265-82
112. Dandara C, Ballo R, Parker MI. CYP3A5 genotypes and risk of oesophageal cancer in two South African populations. Cancer Lett 2005;225:275-82
113. Dandara C, Basvi PT, Bapiro TE, et al. Frequency of -163 C>A and 63 C>G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations. Clin Chem Lab Med 2004;42:939-41
114. Dandara C, Lombard Z, Du Plooy I, et al. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics 2011;12:1663-70
115. Warnich L, Drogemoller BI, Pepper MS, et al. Pharmacogenomic research in South Africa: lessons learned and future opportunities in the rainbow nation. Curr Pharmacogenomics Person Med 2011;9:191-207
116. van der Weide J, Hinrichs JW. The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. Clin Biochem Rev 2006;27:17-25
117. Staehli Hodel EM, Csajka C, Ariey F, et al. Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania. Antimicrob Agents Chemother 2013;57:950-8
118. Wennerholm A, Johansson I, Massele AY, et al. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Pharmacogenetics 1999;9:707-14
119. Aklillu E, Persson I, Bertilsson L, et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996;278:441-6
120. Arnaldo P, Thompson RE, Lopes MQ, et al. Frequencies of cytochrome P450 2B6 and 2C8 allelic variants in the mozambican population. Malays J Med Sci 2013;20:13-23
121. Fuselli S, de Filippo C, Mona S, et al. Evolution of detoxifying systems: the role of environment and population history in shaping genetic diversity at human CYP2D6 locus. Pharmacogenet Genomics 2010;20:485-99
122. Bienvenu E, Swart M, Dandara C, et al. Frequencies of single nucleotide polymorphisms in cytochrome P450 genes (CYP1A2, 2A6, 2B6, 3A4 and 3A5) in a Rwandan population: difference to other African populations. Curr Pharmacogenomics Person Med 2013;11:237-46